Mariaileen Sourwine, MD
Internal Medicine · Arnold, MDNPI 1528227378
Payments from drug & device makers
What this record shows
Boehringer Ingelheim International GmbH accounts for 78.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,303 and has fallen 96.7% since, to $43 in 2025.
Across 27 payments — averaging $56.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Boehringer Ingelheim$77
- Abbott$53
- AbbVie$46
- Pfizer$31
- Lilly USA, LLC$22
- plus $102 from 6 others
Across 140 payments — averaging $4073.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$552K
- Boehringer Ingelheim International GmbH$19K
What the payments were for
- Travel & lodging$71447%
- Food & beverage$82253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,204 |
| Boehringer Ingelheim | 3 | $77 |
| Abbott | 3 | $53 |
| AbbVie | 2 | $46 |
| Pfizer | 1 | $31 |
| Lilly USA, LLC | 1 | $22 |
| Resmed Corp | 1 | $21 |
| Organon | 1 | $19 |
| Amgen | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Biotronik Inc. | 1 | $15 |
How this compares
$1,536 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 22 | $74,070 |
| EliquisApixaban | 31 | $47,466 |
| JardianceEmpagliflozin | 17 | $28,743 |
| OzempicSemaglutide | 12 | $20,970 |
| JanuviaSitagliptin Phosphate | 19 | $19,970 |
| TrulicityDulaglutide | 18 | $19,154 |
| XareltoRivaroxaban | 12 | $18,044 |
| MounjaroTirzepatide | 11 | $17,477 |
| Atorvastatin Calcium | 254 | $4,003 |
| SynthroidLevothyroxine Sodium | 53 | $3,516 |
| Rosuvastatin Calcium | 138 | $3,457 |
| Losartan Potassium | 169 | $2,783 |
| Levothyroxine Sodium | 190 | $2,384 |
| Duloxetine Hcl | 51 | $2,347 |
| Metoprolol Succinate | 107 | $1,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Synthroid | $46 | $77,58675 claims |
| PfizerEliquis, Paxlovid | $31 | $48,89543 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $22 | $36,63129 claims |
| Boehringer IngelheimJardiance | $77 | $28,74317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Arnold
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
- Matthew MintzBethesda$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.